Molecular Neurobiology

, Volume 46, Issue 1, pp 64–77

Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer’s Disease

  • Ling Li
  • Wei Zhang
  • Shaowu Cheng
  • Dongfeng Cao
  • Marc Parent
Article

DOI: 10.1007/s12035-012-8253-1

Cite this article as:
Li, L., Zhang, W., Cheng, S. et al. Mol Neurobiol (2012) 46: 64. doi:10.1007/s12035-012-8253-1

Abstract

Two major isoprenoids, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, serve as lipid donors for the posttranslational modification (known as prenylation) of proteins that possess a characteristic C-terminal motif. The prenylation reaction is catalyzed by prenyltransferases. The lipid prenyl group facilitates to anchor the proteins in cell membranes and mediates protein–protein interactions. A variety of important intracellular proteins undergo prenylation, including almost all members of small GTPase superfamilies as well as heterotrimeric G protein subunits and nuclear lamins. These prenylated proteins are involved in regulating a wide range of cellular processes and functions, such as cell growth, differentiation, cytoskeletal organization, and vesicle trafficking. Prenylated proteins are also implicated in the pathogenesis of different types of diseases. Consequently, isoprenoids and/or prenyltransferases have emerged as attractive therapeutic targets for combating various disorders. This review attempts to summarize the pharmacological agents currently available or under development that control isoprenoid availability and/or the process of prenylation, mainly focusing on statins, bisphosphonates, and prenyltransferase inhibitors. Whereas statins and bisphosphonates deplete the production of isoprenoids by inhibiting the activity of upstream enzymes, prenyltransferase inhibitors directly block the prenylation of proteins. As the importance of isoprenoids and prenylated proteins in health and disease continues to emerge, the therapeutic potential of these pharmacological agents has expanded across multiple disciplines. This review mainly discusses their potential application in Alzheimer’s disease.

Keywords

Isoprenoids Protein prenylation Statins Bisphosphonates Prenyltransferase inhibitors Alzheimer’s disease 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Ling Li
    • 1
  • Wei Zhang
    • 1
  • Shaowu Cheng
    • 1
  • Dongfeng Cao
    • 1
  • Marc Parent
    • 1
  1. 1.Department of Experimental and Clinical PharmacologyUniversity of MinnesotaMinneapolisUSA